Navigation Links
Inhibitor That Blocks Host Receptors Found To be Effective In Treating Anthrax

A team of American and Canadian scientists from Rensselaer Polytechnic Institute in Troy, N.Y., and the University of Toronto have developed a new anthrax// inhibitor that blocks the host receptors where anthrax toxin attaches in the body.

The researchers said that the inhibitor was able to bind to multiple sites on the host receptor making it much for potent than the inhibitors that binds to single site. The researchers found that the new approach led to a 50,000-fold increase in activity to block multiple binding sites when compared with a more conventional inhibitor. They found that all six rats that got these inhibitors were protected against the toxins and had no adverse effects.

Anthrax is a serious disease caused by bacteria, Bacillus anthracis, which can affect both human and animals. The B. anthracis when inhaled, as when used as a biological weapon, is much more serious and can be fatal despite treatment with antibiotics. Most therapies including antibiotics used to treat anthrax are targeted against the bacteria or the toxin released by the bacteria that damages the host organism.

However, these bacteria can become resistant to antibiotics over time, and resistance can also be engineered intentionally into a germ as when used as a biological weapon. Also, the antibiotic used only slows the progression of infection, but do not counter the effects of the toxins once an infection takes hold.

However, the use of anthrax inhibitor could help address this issue as they block the receptor sites used by the bacteria to gain a lethal foothold in the body and thus can help reduce the number of deaths caused by inhaled anthrax once it is fully developed. According to the federal Centers for Disease Control and Prevention, inhaled anthrax still has a fatality rate of 75 percent even after antibiotics are given.

Ravi Kane, an associate professor of chemical and biological engineering at Rensselaer Polyte
'"/>




Page: 1 2

Related medicine news :

1. Aromatase Inhibitors drug Femara after Tamoxifen therapy protects from breast cancer recurrence
2. Macrophage Inhibitory Factor Causes Multiple Sclerosis Progression
3. Rejuvenation of Stem cells by GSK-3 Inhibitor
4. LipB Protein Inhibitors Help To Fight Against TB
5. Birth Defects Link With ACE Inhibitor Use, FDA Reports
6. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
7. ACE Inhibitors For Vascular Disease Patients
8. Reducing the Risk of Protease Inhibitor-Related Atherosclerosis
9. Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model
10. New Protein Inhibitor Halts Growth Of Cancerous Cells
11. Early Switch to an Aromatase Inhibitor Increases Survival
Post Your Comments:
(Date:5/6/2015)... (PRWEB) May 06, 2015 Wolters ... healthcare professionals and students, announced today that in a ... confirmed that use of the clinical decision support resource ... the end of 2014, UpToDate users in more than ... topics per month, on average. In Germany alone, 95% ...
(Date:5/6/2015)... TX (PRWEB) May 06, 2015 ... 1,000 user mark after launching in mid-February. The company ... candidates who have previous experience in the industry. Likewise, ... profession. , According to Kyle Johnson, CTO, unique traffic ... to the first month: "Each new job posting brings ...
(Date:5/6/2015)... 06, 2015 Locally owned, Greek olive oil ... this past week as having one the best Extra Virgin ... from the Peloponnese region of Greece and known as ... the category of Medium Olive Oil, which is defined by ... With over 700 producer applicants from 25 different countries ...
(Date:5/6/2015)... Dr. Vito C. Quatela, one of upstate New York’s ... medical mission trip to Hanoi, Vietnam with the HUGS Foundation ... and other deformities of the face. , During the 10-day ... 26, Dr. Quatela and his team performed microtia surgeries on ... the outside of the ear is underdeveloped. This condition is ...
(Date:5/6/2015)... Los Angeles, California (PRWEB) May 06, 2015 ... has secured its first round of VC funding and ... , The enterprise class embeddable software enables applications ... transform data as it moves between systems and locations. ... the HyperTransfer technology moves files at line speed, independent ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Job Seekers Turn to JobMedic to Find Healthcare Positions - JobMedic.com Reaches 1,000 User Milestone 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 2Health News:Dr. Vito Quatela Completes Successful 10-Day Medical Mission Trip to Hanoi, Vietnam 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4
... completely implantable artificial heart was approved by the U.S. ... heart has been approved for patients with severe heart ... ,Under the FDA's Humanitarian Use Device provisions, ... However, it restricts the use of more than 4,000 ...
... 300 million poultry next month against bird flu.// ... large-scale criticism over the country's efforts to stamp out ... mass vaccination today. Indonesia has the world's highest human ... in the world and scientists and the World Bank ...
... An engineer has developed a new system that could help ... ,An engineer Fernando Silvio Nu?o Almirantearena has developed a ... heart attack, brain stroke or high blood pressure, by determining ... techniques. Fernando has outlined in his thesis for PhD the ...
... in the Journal of Clinical Investigation and the September issue ... that a new drug helps in reducing the risk of ... flow in diseased arteries. The new drug developed by ... by free radicals, which helps in dilatation of the arteries. ...
... worked at Ground Zero after 9/11 are struggling with serious ... advocates.// "When we were needed on 9/11, no one asked ... said Lucelly Gil, who was present in the disaster zone. ... illegal immigrants to work in danger zone without providing the ...
... asked EU health authorities to re-examine data related to ... Committee for Medicinal Products for Human Use (CHMP) had ... cancer need new treatment options like Tarceva, which has ... and has already been approved for this indication in ...
Cached Medicine News:Health News:First Implantable artificial heart gets FDA’s approva 2Health News:Indonesia To Conduct Mass Vaccination Of Poultry 2Health News:A New System Developed For Studying The Condition Of The Human Arterial System 2Health News:A New Drug That Could Revolutionize Management Of Heart Disease 2
(Date:5/6/2015)... , May 06, 2015 Research and Markets ... addition of the "Asia-Pacific Internal Trauma Fixation ... Analysis and Forecast To 2019" report to ... Fixation Devices market is estimated to grow at ... Factors, such as technological advancement, rising incidences of ...
(Date:5/6/2015)... DIEGO , May 6, 2015  MEI Pharma, Inc. ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at the Bank of America Merrill Lynch ... 8:00 a.m. Pacific time from the Encore at the Wynn ... of the presentation can be accessed at www.meipharma.com . ...
(Date:5/6/2015)... 6, 2015 Adaptive Biotechnologies, a leader ... T-cell and B-cell receptors in the immune system, ... financing round with a $195 million investment to ... led by Matrix Capital Management and included other ... Springs Capital and an additional large healthcare investor, ...
Breaking Medicine Technology:Asia-Pacific Internal Trauma Fixation Devices (Internal Trauma Fixation Plates, Screws, Rod Wires & Pins, Fusion Nails) Market 2015 2MEI Pharma to Present at Bank of America Merrill Lynch Health Care Conference 2Adaptive Biotechnologies Enhances Leading Position in Growing Immunosequencing Market with Completion of $195 Million Investment 2
... MYL ) today announced its financial results for the ... , Adjusted diluted EPS of $0.52 for the three ... prior year period, an increase of 18%; , Adjusted ... 31, 2012 compared to $1.45 billion for the same prior year ...
...  Galenea Corp., a leader in the rapidly emerging ... Stanley Medical Research Institute (SMRI) will provide $6 ... development of Galenea,s innovative pro-cognitive discovery program and ... treatment of schizophrenia and other psychiatric disorders.  The ...
Cached Medicine Technology:Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 2Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 3Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 4Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 5Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 6Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 7Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 8Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 9Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 10Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 11Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 12Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter 13Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program 2Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program 3
Bio-Rad's ScanGel® cards for ABO reverse grouping, antibody screening and crossmatching include - ScanGel Neutral, ScanGel Coombs, Anti-IgG, -C3d (AHG), ScanGel Coombs + Neutral, ScanGel Anti-Ig...
... The Criterion Dodeca cell, a component of ... run up to 12 Criterion gels in a ... (13.3 x 8.7 cm) than the traditional mini ... strips to give you the optimal combination of ...
... Plus Dodeca cell accommodates up to 12 ... first-dimension runs in the PROTEAN IEF system, ... format. The PROTEAN Plus Dodeca cell's cooling ... electrodes, allow consistent, high-resolution results. The handcasting ...
... The ElectroXpress gel electrophoresis system mirrors a ... high-throughput screening of PCR products to take ... the source (96-well) plate. Loading can be carried ... the first time in the industry two ...
Medicine Products: